KR20230092348A - Composition for inhibiting body odor, serum secretion, and dandruff comprising Lagerstroemia indica extracts as an active ingredient - Google Patents

Abstract

The present invention provides a composition for preventing, improving, or treating body odor, sebum secretion, or dandruff, containing a cruciferous flower extract as an active ingredient. The active ingredient of the composition of the present invention, the crape myrtle flower extract, inhibits the growth of body odor-causing microorganisms such as head odor, body odor, foot odor, etc., and thereby inhibits the production of odor-inducing substances, inhibits sebum secretion, and inhibits dandruff bacteria. Because of its excellent inhibitory activity, it is useful as a cosmetic for preventing and improving body odor, sebum secretion, and dandruff, a skin external preparation, a quasi-drug, and a pharmaceutical composition for preventing and treating these related diseases.

Description

Composition for inhibiting body odor, sebum secretion, and dandruff comprising an extract of crape myrtle flower as an active ingredient

The present invention relates to a composition for inhibiting body odor, sebum secretion, or dandruff, comprising an extract of cruciferous plant as an active ingredient. More specifically, the effect of inhibiting the growth of skin microorganisms that cause body odor to inhibit the characteristic odor caused by the metabolic action of bacteria and reducing the scalp odor by inhibiting the secretion of sebum and the activity of dandruff bacteria that act as the cause of scalp odor It relates to a cosmetic, pharmaceutical, external preparation for skin, and quasi-drug composition comprising as an active ingredient an extract of cruciferous biloba, which has an effect of inhibiting sebum secretion and dandruff.

There are two types of sweat glands in the human body, one is the apocrine sweat gland, which is distributed throughout the scalp and body, and the other is the eccrine sweat gland, which is distributed in the hairy part and armpits. .

Sweat secreted from the sweat glands of the human body is colorless and odorless in itself, but in the process of decomposition of fat, protein, or sebum contained in sweat, unpleasant body odors such as head odor, body odor, and foot odor occur. This decomposition is mainly performed by microorganisms, and microorganisms related to body odor include Cutibacterium , Corynebacterium , and Staphylococcus hominis (Yamazaki et. al. Anti -Aging Med., 7,60-65,2010). In addition, there is a dandruff bacterium ( Malassezia ) associated with the smell of the scalp.

In addition, body odor may be caused by excessive sweating due to intense exercise or stress, secretion of sebum, and secretion of proteins and fats along with sweat due to eating fatty foods.

These body odors may show different specific odors depending on gender and age, such as men, women, babies, and the elderly.

The human microbial community plays an important role in the development of human body odor. Among them, microorganisms belonging to the genus Staphylococcus , Cutibacterium , and Corynebacterium exist as dominant microorganisms in the scalp, armpits, and feet. The metabolism of these microbial communities is also pointed out as the cause of body odor. As an example, C-Sβ-lyase secreted by Staphylococcus hominis converts Cys-Gly-3M3SH, a 'odorless compound' secreted from sweat glands, into 3M3SH, a thioalcohol, and disperses it. released or released out of the cell. At this time, the dispersed or released thioalcohol is a key substance that causes the underarm odor (Michelle Rudden et. al., Nature, 12500, 2020). In addition, Staphylococcus uses lactate (L-lactate) as a metabolic substrate to produce diacetyl, a substance that emits an unpleasant odor (Takeshi Hara et. al. PLoS One ). , 9(11): e111833, 2014). Therefore, biological control of microorganisms that produce volatile substances that cause body odor, such as odor, through efficacy studies using natural extracts capable of inhibiting major odor-causing strains, Staphylococcus and Corynebacterium , and thereby Body odor can be reduced by preventing conversion of precursor molecules into volatile substances.

The scalp is one of the representative body parts that cause a unique body odor, and excessively secreted sebum acts as the main cause of scalp odor. The sebaceous glands on the scalp exist at a density twice as high as that of the face, and the excessively secreted sebum progresses to seborrheic dermatitis, causing hair loss, and reacts with wastes present in the hair to cause scalp inflammation and odor. Malassezia , a representative pathogenic bacterium that consumes sebum, decomposes triglycerides in sebum into saturated and unsaturated fatty acids, and these fatty acids mediate inflammation including scalp odor, scalp erythema, and scalp itching (Byung In Ro, et al. Invest Derm Symp Proc, 10: 194-197, 2005, DeAngelis YM et al. J Invest Derm Symp Proc 10: 295-297, 2005). Therefore, it is possible to improve scalp odor by inhibiting excessive secretion of sebum and inhibiting the activity of dandruff bacteria, which cause scalp odor.

Lagerstroemia indica ) is a big tree with large leaves of the Buddha family. It grows up to 3-7m in height. Its origin is China, and it is mainly planted and cultivated as a garden tree. Among the various names of crape myrtle flowers, it is known as 'baekilhong' in Korea. Because of the long blooming period, it is also called 'tree crape myrtle'. The nature of the flower is cold, the taste is slightly sour, and its representative effects include treating cystitis and improving poor circulation. In the private sector, there are ways to dry the flowers of the cruciferous tree in the shade and drink them as tea or fry them in oil, and eggplants are known to help treat cystitis, which is common in women.

Korean Patent Laid-Open No. 10-2014-0099849 (published on August 13, 2014) about cruciferous tree has antioxidant effect, MMP-1 production inhibitory effect, collagen biosynthesis effect, melanin production inhibitory effect, preservative Korean Patent Laid-open Publication No. 10-2011-0050938 (published on May 17, 2011) discloses a pharmaceutical composition for preventing or improving allergies containing an extract of the whole plant of Baerensis as an active ingredient. , Korean Patent Laid-open Publication No. 10-2004-0039132 (published on May 10, 2004) discloses a cosmetic composition for improving skin wrinkles containing a flower extract of Mokbaekilhong.

However, little research has been done on the body odor improvement efficacy of crape myrtle flowers so far.

Accordingly, the inventors of the present invention, while searching for a substance for improving body odor, confirmed the ability to inhibit the activity of odor-causing microorganisms and the secretion of sebum in order to solve the above problems. As a result, the present invention was completed by confirming that the crape myrtle flower extract can effectively suppress sebum secretion, which is one of the causes of odor, as well as inhibit microbial activity related to odor induction.

One object of the present invention is to provide a composition for the prevention, improvement, or treatment of body odor, sebum secretion, or dandruff, characterized in that it contains a crape myrtle flower extract as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for preventing or improving body odor, sebum secretion, or dandruff, comprising a crape myrtle flower extract as an active ingredient.

Another object of the present invention is to provide a composition for external application for skin for preventing or improving body odor, sebum secretion, or dandruff, comprising a cruciferous flower extract as an active ingredient.

Another object of the present invention is to provide a quasi-drug composition for preventing or improving body odor, sebum secretion, or dandruff, comprising a cruciferous flower extract as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of bronchospasm, axillae, or dandruff, comprising an extract of a crape myrtle flower as an active ingredient.

In order to solve the above technical problem, the present invention is a composition for preventing, improving or treating body odor, sebum secretion, or dandruff containing a cruciferous flower extract as an active ingredient, and a composition for preventing, improving or treating body odor, sebum secretion, or dandruff by administering the composition to a subject. A method for preventing, improving, or treating dandruff is provided.

In the present invention, "Bagerstroemia ( Lagerstroemia indica )" is a big tree of reeds of the Buddha flower family. It grows up to 3-7m in height. Its origin is China, and it is mainly planted and cultivated as a garden tree. The bark is light reddish brown, and as it falls in thin pieces, white patterns are formed, and the bark is thin and very smooth. The front side of the leaf is glossy and hairless, and the back side has hairs along the veins. The panicle at the end of the branch is 10 to 20 cm long, and red flowers bloom in clusters. Among the various names of crape myrtle flowers, it is known as 'baekilhong' in Korea. Because of the long blooming period, it is also called 'tree crape myrtle'. Flowers are collected when they are in bloom. Flowers are cold in nature and slightly sour in taste.

In the present invention, "extract" refers to a liquid component obtained by immersing a desired substance in various solvents, then extracting and fractionating a substance at room temperature or at elevated temperature for a certain period of time, and a solid component obtained by removing the solvent from the liquid component. means the result of In addition, in addition to the above results, it can be comprehensively interpreted as including all dilutions of the results, concentrates thereof, adjusted products, and purified products thereof.

The crape myrtle flower extract can be extracted using a conventional solvent known in the art, and the extracted liquid can be used in liquid form or concentrated and / or dried. At this time, the solvent is, for example, (a) water, (b) anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) a mixed solvent of the lower alcohol and water , (d) acetone, (e) ethyl acetate, (f) chloroform or (g) 1,3-butylene glycol as an extraction solvent. Preferably, extraction may be performed using water, methanol, ethanol or butanol. More preferably, it can be extracted using water or ethanol. Most preferably, it can be extracted using water, especially hot water. Depending on the organic solvent to be extracted, the degree of extraction and loss of the active ingredient of the extract may vary, so select and use an appropriate organic solvent. The extraction method is not particularly limited, and includes, for example, cold needle extraction, ultrasonic extraction, reflux cooling extraction method, and the like.

In one specific embodiment of the present invention, the cruciferous flower extract can be obtained through a conventional purification process in addition to the extraction method using the extraction solvent. For example, obtained through various additional purification methods, such as separation using an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Even using the fraction, it is possible to obtain a cruciferous flower extract.

In the present invention, "body odor" is an odor emitted from the skin of the human body, such as the scalp, armpits, and feet, and includes head odor, body odor, foot odor, and groin odor. The cause of body odor is caused by the generation of a characteristic odor that causes discomfort in the process of decomposition of sweat secreted by sweat glands of the human body or substances secreted and contained with sweat, for example, sebum, fat, or protein. The decomposition is mainly performed by the metabolic action of microorganisms belonging to the genus Staphylococcus , Cutibacterium and Corynebacterium .

The active ingredient of the composition of the present invention, the crape myrtle flower extract, exhibits the effect of inhibiting the growth of microorganisms of the genus Staphylococcus and Corynebacterium that cause body odor, thereby preventing, improving and treating body odor. have an effect

The Staphylococcus genus microorganisms include, but are not necessarily limited to, Staphylococcus hominis and Staphylococcus haemolyticus .

Microorganisms of the genus Corynebacterium include, but are not necessarily limited to, Corynebacterium xerosis or Corynebacterium glutamicum .

In addition, since the cruciferous flower extract, which is an active ingredient of the composition of the present invention, exhibits an effect of suppressing the secretion of sebum that causes body odor, it has effects of preventing, improving, and treating body odor as well as preventing, improving, and treating sebum secretion. have an effect

In addition, the active ingredient of the composition of the present invention, the crape myrtle flower extract, suppresses the secretion of sebum that causes body odor, especially scalp sebum and head odor (scalp odor) caused by the activity of dandruff bacteria, and prevents dandruff bacteria ( Malassezia furfur ) Since it exhibits an effect of inhibiting growth, it has effects of preventing, improving and treating body odor as well as preventing, improving and treating dandruff.

The term "prevention" or "improvement" in the present invention refers to any action that inhibits or delays the occurrence of body odor, sebum secretion, or dandruff by administration of the composition according to the present invention, and "treatment" refers to any action according to the present invention It refers to all actions that improve or beneficially change body odor, sebum secretion, or symptoms of a subject suspected of or having dandruff by administration of the composition. Meanwhile, the present specification may use the term "inhibition" as equivalent or similar to "prevention", "improvement", or "treatment".

The term "administration" in the present invention means introducing the composition of the present invention to a subject by any appropriate method, and the route of administration of the composition of the present invention is through various oral or parenteral routes as long as it can reach the target tissue. can be administered.

The administration method of the composition according to the present invention is not particularly limited, and may follow a method commonly used in the art. As a non-limiting example of the administration method, the composition may be administered by oral administration or parenteral administration. Preferably parenteral administration, more preferably it can be applied by topical application (topical application) by application.

Specifically, the composition of the present invention is directly applied or spread on the skin where body odor, sebum secretion, or dandruff such as the scalp, armpits, feet, groin, face, calves, forearms, stomach, etc. can be used

The composition containing the crape myrtle flower extract as an active ingredient may be included in an amount of 0.00001 to 15.0% by weight, preferably 0.0001 to 10% by weight, more preferably 0.0001 to 5% by weight based on the total weight of the total composition. If the cruciferous flower extract is less than 0.0001% by weight, the efficacy is weak. In addition, when it exceeds 15% by weight, the increase in the effect due to the increase in the content is insignificant, and a problem in that the stability of the formulation is not secured may occur.

In one specific aspect, the present invention provides a cosmetic composition for preventing or improving body odor, sebum secretion, or dandruff, comprising the crape myrtle flower extract as an active ingredient.

The crape myrtle flower extract may additionally include components commonly used in cosmetic compositions in addition to the cruciferous flower extract as an active ingredient. For example, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavoring agents, and conventional adjuvants, and carriers may be included.

The cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , It may be formulated as an oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it may be prepared in formulations such as nutrient cream, astringent lotion, softening lotion, lotion, essence, nutrient gel or massage cream.

When the formulation of the cosmetic composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide as a carrier component this can be used

When the formulation of the cosmetic composition is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, especially in the case of a spray, additionally chlorofluorohydrocarbon, propellants such as propane/butane or dimethyl ether.

When the formulation of the cosmetic composition is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, fatty acid esters of glycerol, polyethylene glycol or sorbitan.

When the formulation of the cosmetic composition is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspension agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth and the like may be used.

When the formulation of the cosmetic composition is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid Amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

In another specific aspect, the present invention provides a pharmaceutical composition for the prevention and treatment of bronchospasm, axillae, or dandruff, comprising the cruciferous flower extract as an active ingredient.

The pharmaceutical composition may include a pharmaceutically acceptable carrier in addition to containing the crape myrtle flower extract as an active ingredient.

Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, including, but not limited to, calcium silicate, microcrystalline cellulose, polyvininpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil; it is not going to be The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like in addition to the above components.

The pharmaceutical composition of the present invention may be administered through various routes such as oral or parenteral, preferably parenteral administration, and more preferably topical application by application.

A suitable dosage of the pharmaceutical composition of the present invention is variously prescribed depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and response sensitivity. It can be. The oral dosage of the pharmaceutical composition of the present invention is within the range of 0.001-100 mg/kg (body weight) for adults. In addition, in the case of an external agent, it is recommended to apply it 1 to 5 times a day in an amount of 1.0 to 3.0 ml based on adults and continue for at least one month. However, the dosage is not intended to limit the scope of the present invention.

The pharmaceutical composition of the present invention is prepared in unit dosage form by formulation using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by those skilled in the art. or it may be prepared by incorporating into a multi-dose container. At this time, the formulation may be in the form of a solution, suspension, syrup or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, powder, granule, tablet or capsule, and may additionally contain a dispersing agent or stabilizer.

In another specific aspect, the present invention provides a method for preventing, improving, or treating body odor, sebum secretion, or dandruff, which includes administering a composition containing the cruciferous crested flower extract as an active ingredient.

As used herein, the term "subject" may refer to all animals, including humans, who have or may have body odor, excessive secretion of sebum, or dandruff. The animal may be not only humans but also mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, and cats that require treatment for similar symptoms, but are not limited thereto.

Specifically, the prevention, improvement or treatment method of the present invention may include administering the composition in a pharmaceutically effective amount to a subject who has or is at risk of developing body odor, excessive secretion of sebum, or dandruff. The administration method is as described above.

The prevention may refer to any action that suppresses or delays body odor, sebum secretion, or dandruff by administering the composition for preventing, improving, or treating body odor according to the present invention to a subject.

In addition, the improvement or treatment may refer to any action that improves or benefits body odor, sebum secretion, or dandruff by administering the composition of the present invention to a subject suspected of having body odor, sebum secretion, or dandruff.

In another specific aspect, the present invention provides a composition for external application for skin for preventing or improving body odor, sebum secretion, or dandruff, comprising the cruciferous flower extract as an active ingredient.

The composition for external application for skin according to the present invention may be formulated by containing a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example solutions, gels, solids, anhydrous pasty products, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) and It may be provided in the form of a non-ionic vesicular dispersion or in the form of a cream, toner, lotion, powder, ointment, spray, pack or conceal stick. It can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.

In addition, the composition for external application for skin according to the present invention includes a fatty substance, an organic solvent, a solubilizing agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, and an ionic type. or nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other commonly used in cosmetics. It may contain adjuvants commonly used in the field of cosmetology or dermatology, such as ingredients. The adjuvant is introduced in an amount generally used in the field of cosmetology or dermatology.

In another aspect, the present invention provides a quasi-drug composition for preventing or improving body odor, sebum secretion, or dandruff, containing the cruciferous flower extract as an active ingredient.

The quasi-drugs refer to products with milder effects than pharmaceuticals among products used for the purpose of diagnosing, treating, improving, mitigating, treating, or preventing human or animal diseases. For example, quasi-drugs under the Pharmaceutical Affairs Act exclude items used for pharmaceutical purposes, and include products used for the treatment or prevention of human/animal diseases, products with minor or no direct action on the human body, and the like. Specifically, the quasi-drug may include external skin preparations and personal hygiene products. More specifically, it may be deodorant, disinfectant cleaner, shower foam, gargreen, wet tissue, detergent soap, hand wash, or ointment, but is not limited thereto.

When the composition according to the present invention is used as a quasi-drug additive, the composition may be added as it is or used together with other quasi-drugs or quasi-drug ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use.

The cruciferous flower extract of the present invention is extracted from a natural plant, and even when used as a composition for preventing, improving, or treating body odor, sebum secretion, or dandruff, it may have fewer side effects than general synthetic compounds, so it can be safely included and usefully used. can

The cruciferous flower extract of the present invention Staphylococcus hominis ( S. hominis ), Staphylococcus haemolyticus ( S. haemolyticus ), and Corynebacterium xerosis ( C. xerosis ) , Corynebacterium glutamicus ( C. glutamicus ) has excellent antibacterial efficacy, inhibits sebum secretion, which is one of the causes of body odor, and has antibacterial efficacy against dandruff bacteria ( Malassezia furfur ) of the scalp, which is one of the causes of head odor It is excellent, and has excellent preventive, ameliorative, and therapeutic effects on body odors such as head odor, body odor, foot odor, and groin odor. In addition, the crape myrtle flower extract of the present invention can relieve excessive sebum secretion or dandruff due to its sebum secretion inhibitory effect and excellent antibacterial activity against dandruff bacteria. In addition, the cruciferous flower extract of the present invention is a natural plant-derived extract unlike conventional chemical compounds, so there is no concern about side effects on the human body.

1 shows the antibacterial activity of a cruciferous flower extract against Staphylococcus hominis and Staphylococcus haemolyticus , which are one of the body odor causative bacteria according to an embodiment of the present invention, by a disk diffusion method. is the result of an experiment.
Figure 2 shows the antibacterial activity of a cruciferous flower extract against Corynebacterium xerosis and Corynebacterium glutamicus , which are one of the body odor causative bacteria according to an embodiment of the present invention, by a disk diffusion method. is the result of an experiment.
Figure 3 is a graph showing the sebaceous cell differentiation inhibitory ability by the cruciferous crested flower extract according to an embodiment of the present invention by quantifying it.
4 is a result of testing the activity inhibitory ability of Malassezia furfur- derived lyapase (lipase) by the cruciferous flower extract according to an embodiment of the present invention.

Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .

Example 1: Preparation of crape myrtle flower extract

After washing the flowers of Chinese crucian carp, they were dried in the shade at 20 ° C to 35 ° C, and then pulverized so that the particle size was 1 mm or less. After immersing 100 g of the pulverized cruciferous flower powder in 70% ethanol solvent, ultrasonic extraction was performed for 48 hours, and the obtained extract was filtered using filter paper (Advantec, No. 2). The filtrate was concentrated under reduced pressure to prepare an extract.

Example 2: Antibacterial efficacy test of crape myrtle flower extract against 4 types of body odor causative bacteria

In the present invention, body odor causative bacteria Staphylococcus hominis ( Staphylococcus hominis ), Staphylococcus haemolyticus ( Staphylococcus haemolyticus ), Corynebacterium xerosis ( Corynebacterium xerosis ), Corynebacterium glutamicus ( Corynebacterium glutamicus ) The concentration of the cruciferous flower extract was prepared at 20-50 mg per mL for the four microorganisms and tested by the disc diffusion method. The culture medium of the four strains was used by adding 0.5% sodium chloride to nutrient broth. Each bacterium was diluted to 1×10 ⁶ CFU/ml and inoculated. The extract was dissolved in sterilized water and dropped onto sterilized paper disks (8 mm in diameter) by 40 ul. Ampicillin was used as a standard antibiotic, and 20ul each was instilled on a paper disk. Staphylococcus hominis ( S. hominis ) and Corynebacterium xerosis ( C. xerosis ) were incubated at 30 ° C. for 24 hours, respectively, and Staphylococcus haemolyticus ( S. haemolyticus ) and Corynebacterium glutami Kus ( C. glutamicus ) was cultured at 37 ° C. for 24 hours and 48 hours, respectively. Thereafter, the antibacterial activity was confirmed by measuring the clear zone around the paper disc.

As a result, as can be seen in Table 1 and FIGS. 1 and 2, the cruciferous flower extract was high in activity against the Staphylococcus hominis ( S. hominis ) strain with an average of 8.3 mm at a concentration of 20 mg / ml, and the extract 40 mg / The antibacterial activity was excellent at 11.8 mm and 12.6 mm at ml and 50 mg/ml, respectively. Staphylococcus haemolyticus showed an average clear zone of 4.3 mm at a concentration of 20 mg/ml, and antibacterial activity at 40 mg/ml and 50 mg/ml at 6.7 mm and 8.7 mm, respectively. Among the genus Staphylococcus , it was found that the cruciferous flower extract had high antibacterial activity against Staphylococcus hominis ( S. hominis ). And Corynebacterium zero sis ( C. xerosis ) appeared at an average of 9.3 mm at 20 mg/ml, and at 40 mg/ml and 50 mg/ml, clear zones were formed at 12.0 mm and 13.7 mm. Corynebacterium glutamicus ( C. glutamicus ) showed an average of 9.0 mm at 20 mg/ml, and antibacterial activity was shown at 12.2 mm and 13.5 mm at 40 mg/ml and 50 mg/ml, respectively. It was found that among the body odor-causing bacteria, high antibacterial activity was found in the genus Corynebacterium .

Strains Inhibition zone (mm) of crape myrtle flower extract (mg/ml) Ampicillin 20 40 50 S. hominis 8.3 11.8 12.6 3.3 S. haemolyticus 4.3 6.7 8.7 8.3 C. xerosis 9.3 12.0 13.7 11.7 C. glutamicus 9.0 12.2 13.5 5.5

Example 3: MIC (Minimum Inhibitory concentration) of cruciferous flower extract for 4 types of body odor causative bacteria

The MIC of the crape myrtle flower extract for body odor-causing strains was measured. The culture medium of the four strains was used by adding 0.5% sodium chloride to nutrient broth. After culturing the four strains on a solid agar medium, the colony was diluted in a liquid medium and inoculated and then cultured. The extract of crape myrtle used in this experiment was prepared and used at 50 mg/ml. In a 96 well plate, Staphylococcus hominis ( S. hominis ), Staphylococcus haemolyticus ( S. haemolyticus ) and Corynebacterium glutamicus ( C. glutamicus ) were each 1 × 10 Inoculated with ⁵ CFU / ml and cultured at 37 ℃ for 24 hours, Corynebacterium zero sis (C. xerosis) was inoculated with 1 × 10 ⁶ CFU / ml and cultured at 37 ℃ for 48 hours, the MIC value got it

As a result of measuring the MIC of crucian carp flower extract, as shown in Table 2, cruciferous cruciferous flower extract inhibited the growth of Staphylococcus hominis ( S. hominis ) from a concentration of 20 ppm and Staphylococcus haemolyticus ( S. haemolyticus ) was suppressed from the 312.5 ppm concentration. Corynebacterium zerosis ( C. xerosis ) and Corynebacterium glutamicus ( C. glutamicus ) were found to have MICs from a concentration of 10 ppm, and the extract of cruciferous flowers was found to have excellent antibacterial activity against Corynebacterium. MIC was 10 ~ 312.5 ppm in 4 types of bacteria causing body odor, and the highest antibacterial activity was shown in Corynebacterium . As the cruciferous flower extract exhibits excellent antibacterial activity against the strains of the genus Staphylococcus and Corynebacterium that cause body odor, the extract of crucian carp flower can be used in various ways to improve and prevent body odor. It is expected.

sample MIC (ug/ml) S. hominis S. haemolyticus C. xerosis C. glutamicus crape myrtle flower extract 20 312.5 10 10

Example 4: Measurement of sebum secretion inhibitory effect of crape myrtle flower extract

In order to investigate the effect of the cruciferous flower extract on sebum secretion, the ability of sebum cells to inhibit sebum secretion was measured.

Specifically, sebocytes (Celprogen), which are human sebaceous cells, were cultured in a serum-containing complete medium and then inoculated into a coated 24-well plate (1×10 ⁴ cells). /well), and cultured for 24 hours at 37°C in a 5% CO ₂ incubator. After the crucian carp flower extract was dissolved in DMEM medium containing 1% FBS, each well cultured with palmitic acid was treated and cultured again for 48 hours. After 48 hours, the cell culture supernatant was removed, washed once with PBS, and treated with 4% formaldehyde for 10 minutes. After washing with PBS three times, 10 μg/ml of Nile Red was mixed with PBS at a ratio of 1:100, and the mixture was left at room temperature for 15 minutes. After washing three times with PBS, nuclear staining was performed with Dapi, and after washing three times again, the degree of staining was confirmed under a microscope. Photos obtained by the microscope were analyzed by Image J, and the values are shown in FIG. 3 .

As shown in Figure 3, compared to the sebum production increased by palmitic acid, the cruciferous flower extract exhibited about 43% of sebum production inhibitory ability at 50 ppm.

Example 5: Measurement of activity inhibition of dandruff bacteria

In order to determine whether the cruciferous flower extract inhibits the activity of dandruff bacteria, the activity of inhibiting lipase activity derived from Malassezia furfur was measured.

Specifically, the culture medium of Malassezia puffer is used by adding 1.0% glycerol (Glycerol, Amresco) and 1.0% polysorbate 80 (Polysorbate 80, Sigma-aldrich) to Brain Heart Infusion (Difco) medium. did After culturing Malassezia puffer on a solid agar medium, colonies were inoculated into 4.0 mL of liquid medium and cultured in a shaking incubator at 30 ° C for 24 hours to be used as seed culture. 1.0% seed culture medium was inoculated into this culture broth and cultured again at 30 ° C. for 120 hours in a shaking incubator. After culturing for 120 hours, the supernatant was collected by centrifugation and filtered using a 0.22um (Durapore) membrane filter. The filtrate was concentrated 20 times using a centrifugal filter (Sartorius), and used as Malassezia puffer-derived lipase. In order to measure the lipase activity inhibitory ability of cruciferous flower extract, it was tested using 4-Methylumbelliferyl oleate (4-MUO, Sigma-aldrich) reagent. After adding 10ug/mL Malassezia puffer-derived lipase, 10mM Tris-HCl (pH8.0), 120mM NaCl, 1mM CaCl2, and 50uM 4-MUO to a 96-well plate, the concentration of crape myrtle flower extract It was added separately and reacted at 25°C for 18 hours. After 18 hours of reaction, emission signals were measured using a fluorescence microplate reader. (370 nm excitation, 450 nm emission measurement)

As shown in Figure 4, compared to the control group to which the crucian carp flower extract was not added, the crucian carp flower extract exhibited about 40% of Malassezia puffer-derived lipase activity inhibitory activity at 100 ug / mL.

Example 6: Safety confirmation experiment on human skin of crape myrtle flower extract

In order to confirm that the cruciferous flower extract, which has been found to be effective in removing senescent cells or changing the function and shape of senescent cells into young cells according to the present invention, is safe for human skin, an external skin preparation containing a cruciferous flower extract is prepared. and skin safety verification experiments were performed.

An external preparation for skin containing 1% of the crape myrtle flower extract of Example 1 was prepared with the component contents shown in Table 3 below. To prepare an external skin preparation, purified water, glycerin, and butylene glycol were mixed and dissolved at 70 °C (water phase part), and the remaining ingredients except for the three components and trimethanolamine were dissolved at 70 °C (oil phase part). The oil part was added to the water phase part and stirred with a homomixer (Tokushu Kika, Japan) for primary emulsification, and trimethanolamine was finally added thereto. After removing bubbles generated in the mixed solution, it was cooled to room temperature to prepare an external preparation for skin.

ingredient content (%) control group test group Purified water 72 71 glycerin 8.0 8.0 Butylene Glycol 4.0 4.0 crape myrtle flower extract 0 1.0 caprylic capri triglyceride 8.0 8.0 squalane 5.0 5.0 cetearyl glucuside 1.5 1.5 Sorbitan Stearate 0.4 0.4 cetearyl alcohol 1.0 1.0 Trimethanolamine 0.1 0.1 gross weight 100 100

Using each of the external skin preparations prepared as described above, 30 healthy adults were applied to the upper arm area every other day for a total of 9 cumulative 24-hour patches to measure whether or not the cruciferous flower extract stimulates the skin. .

The patch method used a pin chamber (Finn chamber, Epitest Ltd, Finland). 15 ??l of each of the external preparations for skin was dropped into the chamber, and then the patch was applied. The degree of skin reaction each time was scored using the following empirical formula 2, and the results are shown in Table 4 below.

[Experimental Formula 1]

Average reactivity = [[(reaction index × reactivity) / (total number of subjects × highest score (4 points))] × 100] ÷ number of tests (9 times)

At this time, in the reactivity, ± is given a score of 1 point, + is 2 points, and ++ is 4 points, and when the average reactivity is less than 3, it is determined as a safe composition.

test
matter Number of subjects who responded average
reactivity 1 week 2 weeks 3 weeks Primary Secondary tertiary 4th 5th 6th 7th 8th 9th ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ control group - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.00 test group - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.00 blood test
personnel 30 30 30 30 30 30 30 30 30

In the case of the test group in Table 4, the number of people corresponding to ±, +, and ++ was 0, 0, and 0, respectively, and no response was shown. When calculated according to the above formula, the average reactivity was 0, so it was 3 or less, and the external skin preparations containing crucifera flower extract (test group) did not show a clear cumulative irritation pattern like the control skin external preparations, so it was judged to be safe for human skin. .

The composition of the present invention may be prepared as a formulation example as follows, but is not limited thereto.

Formulation Example 1: Cosmetic formulation

1-1. softening lotion

ingredient weight% crape myrtle flower extract 0.05 glycerin 3.0 butylene glycol 2.0 propylene glycol 2.0 carboxyvinyl polymer 0.1 ethanol 10.0 triethanolamine 0.1 Preservatives, trace colors, trace flavors and trace purified water 82.75 sum 100.0

1-2. Nutrition lotion

ingredient weight% crape myrtle flower extract 0.05 beeswax 4.0 polysorbate 60 1.5 Sorbitan sesquioleate 0.5 liquid paraffin 5.0 squalane 5.0 Caprylic/Capric Triglyceride 5.0 glycerin 3.0 butylene glycol 3.0 propylene glycol 3.0 carboxyvinyl polymer 0.1 triethanolamine 0.2 Preservatives, trace colors, trace flavors and trace purified water 69.65 sum 100.0

1-3. nourishing cream

ingredient weight% crape myrtle flower extract 0.05 beeswax 10.0 polysorbate 60 1.5 Sorbitan sesquioleate 0.5 liquid paraffin 10.0 squalane 5.0 Caprylic/Capric Triglyceride 5.0 glycerin 5.0 butylene glycol 3.0 propylene glycol 3.0 triethanolamine 0.2 Preservatives, trace colors, trace flavors and trace purified water 56.75 sum 100.0

1-4. massage cream

ingredient weight% crape myrtle flower extract 0.05 beeswax 10.0 polysorbate 60 1.5 Sorbitan sesquioleate 0.8 liquid paraffin 40.0 squalane 5.0 Caprylic/Capric Triglyceride 4.0 glycerin 5.0 butylene glycol 3.0 propylene glycol 3.0 triethanolamine 0.2 Preservatives, trace colors, trace flavors and trace purified water 27.45 sum 100.0

1-5. pack

ingredient weight% crape myrtle flower extract 0.05 polyvinyl alcohol 13.0 Sodium Carboxymethyl Cellulose 0.2 allantoin 0.1 ethanol 5.0 nonylphenyl ether 0.3 Preservatives, trace colors, trace flavors and trace purified water 81.35 sum 100.0

Formulation Example 2: Pharmaceutical Formulation

2-1. manufacture of powders

ingredient weight (g) crape myrtle flower extract 2 lactose One

A powder was prepared by mixing the above ingredients and filling in airtight bags.

2-2. manufacture of tablets

ingredient Weight (mg) crape myrtle flower extract 100 corn starch 100 lactose 100 magnesium stearate 2

After mixing the above components, tablets were prepared by tableting according to a conventional tablet manufacturing method.

2-3. Manufacture of capsules

ingredient Weight (mg) crape myrtle flower extract 100 corn starch 100 lactose 100 magnesium stearate 2

After mixing the above ingredients, capsules were prepared by filling gelatin capsules according to a conventional capsule preparation method.

Claims (9)

A cosmetic composition for preventing or improving body odor, sebum secretion, or dandruff, comprising a cruciferous flower extract as an active ingredient. The cosmetic composition according to claim 1, wherein the body odor is at least one selected from the group consisting of head odor, body odor, foot odor, and groin odor. According to claim 1, wherein the body odor is Staphylococcus ( Staphylococcus ) or Corynebacterium ( Corynebacterium ) genus microorganisms of the sweat or the cosmetic composition, characterized in that caused by the metabolism of substances contained in the sweat. The cosmetic composition according to claim 3, wherein the microorganism of the genus Staphylococcus is Staphylococcus hominis or Staphylococcus haemolyticus . The cosmetic composition according to claim 3, wherein the microorganism of the genus Corynebacterium is Corynebacterium xerosis or Corynebacterium glutamicum . The cosmetic composition according to claim 2, wherein the head odor is caused by the activity of scalp sebum and dandruff bacteria. A composition for external application for skin for preventing or improving body odor, sebum secretion, or dandruff, comprising an extract of crucian carp flower as an active ingredient. A quasi-drug composition for preventing or improving body odor, sebum secretion, or dandruff, containing an extract of crucian carp flower as an active ingredient. A pharmaceutical composition for preventing or treating wakiga, axillae, or dandruff, comprising an extract of crape myrtle flower as an active ingredient.

Images